MBX Biosciences (MBX) Stock Price, News & Analysis

Company Overview

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Key Stats

• Today's Range: $20.29 to $21.98
• 50-Day Range: N/A
• 52-Week Range: $20.29 to $26.08
• Volume: 119,463 shs
• Average Volume: 130,066 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MBX Stock Analysis - Frequently Asked Questions

How have MBX shares performed this year?

MBX Biosciences' stock was trading at $21.00 at the beginning of the year. Since then, MBX shares have increased by 1.1% and is now trading at $21.23.
View the best growth stocks for 2024 here.

When did MBX Biosciences IPO?

MBX Biosciences (MBX) raised $163 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 10,200,000 shares at $16.00 per share.

When does MBX Biosciences' quiet period expire?

MBX Biosciences' quiet period expires on Wednesday, October 23rd. MBX Biosciences had issued 10,200,000 shares in its initial public offering on September 13th. The total size of the offering was $163,200,000 based on an initial share price of $16.00. During MBX Biosciences' quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of MBX Biosciences?

Shares of MBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NYSE:MBX
• CUSIP: N/A
• CIK: N/A
• Web: mbxbio.com
• Phone: (317) 659-0200
• Fax: N/A
• Employees: 36
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A